NCT02467478View on ClinicalTrials.gov

Linagliptin's Effect on CD34+ Stem Cells

PHASE4CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

April 30, 2019

Study Completion Date

December 31, 2019

Conditions

Type 2 DiabetesImpaired Renal Function

Interventions

DRUG

Linagliptin

5 mg tablet once daily for 12 weeks

DRUG

Placebo

1 tablet daily for 12 weeks

Trial Locations (1)

20037

The George Washington University Medical Faculty Associates, Washington D.C.

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

George Washington University

OTHER